Results per Page:
Answering WHO’s call with a new way to track how well we’re fighting the flu
Fred Hutch researchers’ immunity data informs global vaccine updates
Fred Hutch researchers receive prestigious R01 awards
NIH-funded awards will support multi-year investigations into HIV reservoirs, biomarkers of vaccine efficacy and how PrEP influences antibody pharmacokinetics
How Fred Hutch scientists tackle world’s top infectious killer, TB
Expertise in immunology and biostatistics underpin foundational work in tuberculosis vaccines, biomarkers and pathology that could usher in a new era
Taming viral threats after lifesaving transplants
From the Boeckh Lab, Vaccine and Infectious Disease Division
Exposing viral vulnerabilities for targeted cancer vaccines
From the Boonyaratanakornkit, Phipps, Pancera, and McGuire Labs, Vaccine and Infectious Disease Division
Dr. Elizabeth Halloran, expert in vaccine trial design and quantitative methods for infectious diseases, transitions to emerita
Infectious disease modeling pioneer helped outline modern precepts for design and analysis of vaccine trials, causal inference with interference; shaped a generation of infectious disease scientists
The benefits of HIV research? Let us count the ways
HIV work has helped shape the FDA, provided drugs for other infections, changed health systems globally and more, say Fred Hutch experts
CD16+ monocytes are the first responders to HIV reactivation
From the Cohn Lab, Vaccine and Infectious Disease Division
Viruses are linked to lung disease in hematopoietic cell transplant recipients
From the Boeckh Lab, Vaccine and Infectious Disease and Clinical Research Divisions
Viral immunologist taps ‘incredible potential’ of immune system
Dr. Paul Thomas will combine computational and empirical approaches to understand the immune repertoire and turn this knowledge into new diagnostic and therapeutic tools
HIV/AIDS research has saved millions of lives globally and led to innovative advances in multiple diseases
Numerous medical advances originate from U.S.-funded HIV research
Experts urge clinical trials network to study infectious disease therapies in immunocompromised patients
More than 6% of Americans are immunocompromised, yet most clinical trials exclude them
HIV reservoir decay rates defined for children receiving ART
From Dr. Daniel Reeves and colleagues, Fred Hutch Vaccine & Infectious Disease Division and UW Global Health
New horizons in infectious disease treatment and prevention in immunocompromised patients
The 5th Symposium on Infectious Disease in the Immunocompromised Host emphasized new opportunities, next generation